原始细胞危象

Aurora 激酶抑制剂

结合至断点簇区域 (BCR) 的 Abelson/T315I 突变。[15]Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA. 2005;102:11011-11016.http://www.pnas.org/content/102/31/11011.fullhttp://www.ncbi.nlm.nih.gov/pubmed/16046538?tool=bestpractice.com不能治愈。[5]O'Brien S, Berman E, Bhalla K, et al; National Comprehensive Cancer Network. Chronic myelogenous leukemia. J Natl Compr Canc Netw. 2007;5:474-496.http://www.ncbi.nlm.nih.gov/pubmed/17509252?tool=bestpractice.com[16]Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002;99:3472-3475.http://bloodjournal.hematologylibrary.org/content/99/9/3472.fullhttp://www.ncbi.nlm.nih.gov/pubmed/11964322?tool=bestpractice.com